Bu araştırmanın amacı ortaöğretim öğrencilerinin dijital okuryazarlık düzeyleri, dijital bağımlılık ve sanal ortam yalnızlık düzeylerinin çeşitli değişkenler açısından betimlenmesidir. Araştırma betimsel tarama modeliyle yürütülmüştür. Araştırmanın çalışma grubunu devlet okullarında öğrenim gören 354 ortaöğretim öğrencileri oluşturmaktadır. Veri toplanmasında Dijital Okuryazarlık Ölçeği, Dijital Bağımlılık Ölçeği ve Sanal Ortam Yalnızlık Ölçeği kullanılmıştır. Elde edilen veriler Anova, T-Testi, ve pearson korelasyon testleri ile incelenmiştir ve şu sonuçlara erişilmiştir: Farklı sınıflarda öğrenim gören öğrencilerin dijital okuryazarlık, dijital bağımlılık ve sanal ortam yalnızlık düzeylerinin benzer düzeydedir. Kız ve erkek öğrencilerin dijital okuryazarlık, dijital bağımlılık ve sanal ortam yalnızlık düzeylerinin benzer düzeydedir. Öğrencilerin dijital okuryazarlık ve dijital bağımlılık düzeyleri arasında doğrusal bir ilişki mevcuttur.
17 October 2022 in Indian Journal of Hematology and Blood Transfusion
Constantly increasing health expenditures lead use of generic molecules and generics of bortezomib have been used for a long time. The aim of this study is to retrospectively examine the effectiveness, side effects and reliability of generic bortezomib in newly diagnosed multiple myeloma (MM) patients. The data of 95 patients who received four cycles of bortezomib as a first- or second-line therapy in a single center were retrospectively recorded. Treatment responses, side effects and progression free survival (PFS) rates have been calculated and compared. Of the 95 patients, 42 used the original and 53 used the generic molecule. Epidemiological data, MM types, genetic risk groups, laboratory values at diagnosis and bortezomib treatment lines (as a first line or second) were evaluated, and there was no statistical difference between the two groups. When the response rates were evaluated with International Myeloma Working Group (IMWG) criteria, there were no significant difference (p: 0,42). Partial response (PR) and above response rates were similar (%81 vs %79,2 p:0,836). PFS values were 42.8 months in the original and 37.8 months in the generic molecule group (p: 0,68). Side effects were seen in 44,2% of patients, and the most common side effects were neuropathy, cytopenias and infections. They were similar in both groups (p: 0,67). Although this retrospective study is limited, it is the first study comparing the original molecule of bortezomib with its generic. There was no statistical difference between the two groups in terms of treatment responses, PFS times and side effects. However, large-scale evaluations can help obtain healthier data on this subject.
Chronic Lymphocytic Leukemia (CLL) and Evans Syndrome represent complex hematologic disorders characterized by distinct yet interconnected pathophysiologies. This case report explores the diagnostic and therapeutic intricacies of managing concurrent CLL and Evans Syndrome in a 59-year-old male patient presenting with fatigue and petechiae. Laboratory findings revealed severe hematologic derangements indicative of advanced CLL and autoimmune hemolytic anemia (AIHA). The diagnostic journey encompassed bone marrow analysis confirming CLL and Coombs positivity suggesting Evans Syndrome, with careful exclusion of immune thrombocytopenia (ITP). Initial therapeutic interventions included steroids and intravenous immunoglobulin (IVIG) for AIHA, alongside eltrombopag for persistent thrombocytopenia. Subsequently, rituximab and venetoclax were initiated for CLL, leading to complete remission. The successful outcome underscores the importance of an integrated therapeutic approach in managing concurrent CLL and Evans Syndrome, offering insights for future clinical management of complex hematologic disorders.